First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been the focus of growing attention as a new option in the treatment of diabetes. Companies have been competing intensely to develop the first-in-class SGLT-2 inhibitors. In Japan, Astellas Pharma’s ipragliflozin is expected to be...read more